Scientific Progam

Company Sponsored Sessions
Back To Section List
	Bausch & Lomb
	Retisert: Fluocinolone acetonide intravitreal implant
	Chairman: Barry Kupperman, USA
	Non infectious posterior uveitis Epidemiology & Classification of uveitis Manfred Zierhut, Germany Advances in diagnosis Bahram Bodaghi, France Fluocinolone acetonide intravitreal implant to treat posterior uveitis: 2-year results of a multi-center clinical trial Albert Vitale, USA EU results Carlos Pavesio, UK Fluocinolone implant slows the progression of diabetic retinopathy A. Pearson, USA
	Merck
	Optimizing Glaucoma Management: Implications of Intraocular Pressure & Ocular Blood Flow
	Chairman: J. Jonas, Germany
	Welcome and introduction Jost Jonas, Germany Long-term results in 24-Hour IOP Control Anastasios Konstas, Greece The role of altered hemodynamics in ocular physiopathology Leopold Schmetterer, Austria Pathogenesis of Glaucoma: Implications of IOP and OBF Alon Harris, USA Panel Discussion Moderator: J. Jonas, Germany
	Novartis
	Efficacy and safety of ranibizumab for the treatment of neovascular AMD
	Welcome and introduction Michael Larsen, Denmark What effect does ranibizumab have on quality-of-life in patients with exudative AMD? Patient-reported outcomes using the VFQ-25 questionnaire Yit Yang, UK Is ranibizumab a safe option for exudative AMD? Combined safety results from Phase III clinical studies of ranibizumab Daniel Pauleikhoff, Germany Are the benefi ts of ranibizumab for exudative AMD maintained in the longer term? Efficacy and safety results from the MARINA study Michael Larsen, Denmark Panel Discussion Conclusion Michael Larsen, Denmark
	Verteporfin's future role in AMD therapy
	Welcome Ursula Schmidt-Erfurth, Austria Evolving Strategies in the Management of Wet AMD Ursula Schmidt-Erfurth, Austria Rationale for Combination Therapy Peter Kaiser, USA Verteporfin in Combination with Ranibizumab Daniel Pauleikhoff, Germany Panel Discussion: Evolving Treatment Guidelines Q&A
	Pfizer
	Changing perspectives in Neovascular AMD treatment
	Aetiology of wet AMD: role of VEGF Salvatore Grisanti, Germany Principles of anti-VEGF aptamer therapy Salvatore Grisanti, Germany Clinical trial results Jordi Mones, Spain
	Senju
	New development of therapeutic modalities against ocular refractory diseases
	Chairpersons: H. Yamashita & H. Sakaki
	Ocular surface reconstruction using tissue engineering technique Shigeru Kinoshiita, Japan Surgical adjuvant for visualizing vitreous body Taiji Sakamoto, Japan